High-Risk Antibiotic Prescribed in 20% of Dental Infection Cases, Study Finds

By The Building Texas Show•
A new study reveals that a high-risk antibiotic is given to 20% of patients with dental infections, highlighting the need for better prescribing practices and diagnostic tools.

Found this article helpful?

Share it with your network and spread the knowledge!

High-Risk Antibiotic Prescribed in 20% of Dental Infection Cases, Study Finds

A recent study has found that a high-risk antibiotic is prescribed to 20% of patients seeking care for dental infections, a statistic that raises concerns about antibiotic stewardship and patient safety. The findings underscore the challenges clinicians face when treating serious dental infections, which can cause excruciating pain and swelling that spreads to the neck, ear, and jaw. Patients often visit emergency departments, urgent care centers, or their primary health provider when they cannot see a dentist in a timely manner, according to the source content.

The study's results are particularly relevant for Texas, where access to dental care can be uneven and where emergency departments frequently serve as a safety net for patients with dental emergencies. The overuse of high-risk antibiotics can lead to adverse drug reactions, contribute to antimicrobial resistance, and increase healthcare costs. For Texas businesses, particularly those in the healthcare and insurance sectors, these findings may prompt a review of prescribing protocols and encourage investment in rapid diagnostic tools that can guide appropriate antibiotic use.

As medical experts continue to spread awareness about the different antibiotics and when they can or cannot be used, enterprises like Co-Diagnostics Inc. (NASDAQ: CODX) are also playing their role by developing molecular diagnostics that can help identify infections and guide treatment decisions. Such innovations are crucial for distinguishing between bacterial and viral infections, thereby reducing unnecessary antibiotic prescriptions. The full study details are available through Read More>>.

The announcement was distributed by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. The platform also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, and social media distribution via IBN to millions of social media followers.

For Texas, the implications are significant. The state is home to a growing life sciences and biotechnology sector, with companies like Co-Diagnostics Inc. (NASDAQ: CODX) pioneering diagnostic solutions. As the study highlights the need for judicious antibiotic use, Texas-based healthcare providers, insurers, and diagnostic companies may find new opportunities to collaborate on antimicrobial stewardship programs. Additionally, the findings could influence state policies on antibiotic prescribing and dental care access, ultimately improving patient outcomes and reducing healthcare costs. The full terms of use and disclaimers are available on the https://www.BioMedWire.com/Disclaimer page.